Looking closer on the reason why many of the tested (in silico) cancer cell lines are sensitive to a disruption of the mevalonate pathway, it was observed that these cells fail to express the cholesterol transporter NPC1L1 and the lipoprotein lipase LPL, involved in the assimilation of lipoproteins from the blood stream. This evidence concerns the gene LPL and cancer.